An Open-Label, Multicenter, Randomized Phase Ib/II Study of Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer.

Trial Profile

An Open-Label, Multicenter, Randomized Phase Ib/II Study of Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs E 7820 (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Sponsors Eisai Inc
  • Most Recent Events

    • 25 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 29 Apr 2014 Trial status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 14 Nov 2013 Planned end date changed from 1 Aug 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top